251 - 275 of 8587 Results
Title
Year
-
RESTRICTEDTitle: Symptomatic Care in Multiple System Atrophy: State of the ArtJournal Name: The CerebellumPublisher: Springer Science and Business Media LLCVol: 22Issue #: 3Start Page: 433End Page: 446Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1007/s12311-022-01411-6Best OA location URL: https://link.springer.com/content/pdf/10.1007/s12311-022-01411-6.pdfCitation Count: 7
-
RESTRICTEDTitle: Digital Technology in Movement Disorders: Updates, Applications, and ChallengesJournal Name: Current Neurology and Neuroscience ReportsPublisher: Springer Science and Business Media LLCVol: 21Issue #: 4Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s11910-021-01101-6Best OA location URL: https://link.springer.com/content/pdf/10.1007/s11910-021-01101-6.pdfCitation Count: 30
- Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson’s Disease2020RESTRICTEDTitle: Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson’s DiseaseJournal Name: CNS DrugsPublisher: Springer Science and Business Media LLCVol: 34Issue #: 6Start Page: 559End Page: 577Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40263-020-00727-3Citation Count: 6
-
RESTRICTEDTitle: 24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical RecommendationsJournal Name: CNS DrugsPublisher: Springer Science and Business Media LLCVol: 35Issue #: 2Start Page: 137End Page: 149Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40263-020-00782-wBest OA location URL: https://link.springer.com/content/pdf/10.1007/s40263-020-00782-w.pdfCitation Count: 17
-
RESTRICTEDTitle: Targeting β-Arrestins in the Treatment of Psychiatric and Neurological DisordersJournal Name: CNS DrugsPublisher: Springer Science and Business Media LLCVol: 35Issue #: 3Start Page: 253End Page: 264Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40263-021-00796-yCitation Count: 8
- Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis2022RESTRICTEDTitle: Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysisJournal Name: CNS DrugsPublisher: Springer Science and Business Media LLCVol: 36Issue #: 12Start Page: 1269End Page: 1283Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40263-022-00963-9Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40263-022-00963-9.pdfCitation Count: 14
-
RESTRICTEDTitle: Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s DiseaseJournal Name: CNS DrugsPublisher: Springer Science and Business Media LLCVol: 36Issue #: 12Start Page: 1249End Page: 1267Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40263-022-00973-7Citation Count: 5
- The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability2021RESTRICTEDTitle: The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and SuitabilityJournal Name: Drugs & AgingPublisher: Springer Science and Business Media LLCVol: 38Issue #: 5Start Page: 355End Page: 373Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40266-021-00853-7Best OA location URL: https://discovery.ucl.ac.uk/10124963/5/Foltynie_Incretin-based_Therapies_Review_CG_24.02.21CA.pdfCitation Count: 6
-
RESTRICTEDTitle: Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's DiseaseJournal Name: DrugsPublisher: Springer Science and Business Media LLCVol: 82Issue #: 10Start Page: 1027End Page: 1053Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40265-022-01747-7Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40265-022-01747-7.pdfCitation Count: 9
- Neutrophil activation in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis of protein markers in blood and cerebrospinal fluid2020RESTRICTEDTitle: Neutrophil activation in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis of protein markers in blood and cerebrospinal fluidJournal Name: Ageing Research ReviewsPublisher: Elsevier BVVol: 62Issue #:Start Page: 101130End Page: 101130Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.arr.2020.101130Citation Count: 26
-
RESTRICTEDTitle: What have we learned from genome-wide association studies (GWAS) in Parkinson's disease?Journal Name: Ageing Research ReviewsPublisher: Elsevier BVVol: 79Issue #:Start Page: 101648End Page: 101648Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.arr.2022.101648Best OA location URL: https://doi.org/10.1016/j.arr.2022.101648Citation Count: 11
- Environmental neurotoxicants and inflammasome activation in Parkinson’s disease – A focus on the gut-brain axis2022RESTRICTEDTitle: Environmental neurotoxicants and inflammasome activation in Parkinson’s disease – A focus on the gut-brain axisJournal Name: The International Journal of Biochemistry & Cell BiologyPublisher: Elsevier BVVol: 142Issue #:Start Page: 106113End Page: 106113Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.biocel.2021.106113Citation Count: 8
-
RESTRICTEDTitle: Mechanisms of NLRP3 activation and pathology during neurodegenerationJournal Name: The International Journal of Biochemistry & Cell BiologyPublisher: Elsevier BVVol: 151Issue #:Start Page: 106273End Page: 106273Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.biocel.2022.106273Citation Count: 10
- Strategies for quantifying the enzymatic activities of glycoside hydrolases within cells and in vivo2023RESTRICTEDTitle: Strategies for quantifying the enzymatic activities of glycoside hydrolases within cells and in vivoJournal Name: Current Opinion in Chemical BiologyPublisher: Elsevier BVVol: 77Issue #:Start Page: 102403End Page: 102403Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.cbpa.2023.102403Citation Count: 0
-
RESTRICTEDTitle: Adapting the proteostasis capacity to sustain brain healthspanJournal Name: CellPublisher: Elsevier BVVol: 184Issue #: 6Start Page: 1545End Page: 1560Publication Date:Open Access(OA) Status: RESTRICTEDLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.cell.2021.02.007Best OA location URL: http://www.cell.com/article/S0092867421001574/pdfCitation Count: 66
-
RESTRICTEDTitle: Orthostatic Hypotension in Parkinson DiseaseJournal Name: Clinics in Geriatric MedicinePublisher: Elsevier BVVol: 36Issue #: 1Start Page: 53End Page: 67Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.cger.2019.09.002Best OA location URL: https://europepmc.org/articles/pmc7029426?pdf=renderCitation Count: 48
-
RESTRICTEDTitle: Human brain connectivity: Clinical applications for clinical neurophysiologyJournal Name: Clinical NeurophysiologyPublisher: Elsevier BVVol: 131Issue #: 7Start Page: 1621End Page: 1651Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.clinph.2020.03.031Citation Count: 70
- Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat2020RESTRICTEDTitle: Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the ratJournal Name: Canadian Journal of Physiology and PharmacologyPublisher: Canadian Science PublishingVol: 98Issue #: 7Start Page: 431End Page: 440Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1139/cjpp-2019-0551Citation Count: 7
-
OPENTitle: Recent Advances on Graph Analytics and Its Applications in HealthcareJournal Name: Proceedings of the 26th ACM SIGKDD International Conference on Knowledge Discovery & Data MiningPublisher: ACMVol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1145/3394486.3406469Best OA location URL: https://dl.acm.org/doi/pdf/10.1145/3394486.3406469Citation Count: 9
-
RESTRICTEDTitle: Initiation of pharmacological therapy in Parkinson's disease: when, why, and howJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 5Start Page: 452End Page: 461Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30036-3Citation Count: 121
- Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias2020RESTRICTEDTitle: Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementiasJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 11Start Page: 951End Page: 962Publication Date:Open Access(OA) Status: RESTRICTEDLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/s1474-4422(20)30314-8Best OA location URL: http://manuscript.elsevier.com/S1474442220303148/pdf/S1474442220303148.pdfCitation Count: 283
-
RESTRICTEDTitle: Progress towards therapies for disease modification in Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 7Start Page: 559End Page: 572Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00061-2Best OA location URL: https://discovery.ucl.ac.uk/10130306/1/Foltynie_Disease%20Modifying%20reviewVersion4_ML2_CLEAN.pdfCitation Count: 157
-
RESTRICTEDTitle: A biological classification of Huntington's disease: the Integrated Staging SystemJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 7Start Page: 632End Page: 644Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00120-xBest OA location URL: https://discovery.ucl.ac.uk/10151755/1/21.08.12%20HD-ISS%20Manuscript%20final%20submitted.pdfCitation Count: 86
-
RESTRICTEDTitle: Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatmentJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 124End Page: 132Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.03.027Best OA location URL: http://www.prd-journal.com/article/S1353802021001206/pdfCitation Count: 25
- Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis2021RESTRICTEDTitle: Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysisJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 52End Page: 57Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.03.009Best OA location URL: http://www.prd-journal.com/article/S1353802021001024/pdfCitation Count: 2